Hagens Berman probes GRAIL after $2.2 billion wipeout tied to trial setback

A securities class action targets disclosures around the NHS-Galleri trial after GRAIL said on Feb. 19, 2026 that the study missed its primary endpoint, sending the stock down more than 50% the next day.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.